PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?
1/5 보강
We review evidence for the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC).
APA
González-Ginel I, Rodriguez-Antolin A, et al. (2026). PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?. European urology focus, 12(1), 31-33. https://doi.org/10.1016/j.euf.2025.11.010
MLA
González-Ginel I, et al.. "PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?." European urology focus, vol. 12, no. 1, 2026, pp. 31-33.
PMID
41353049 ↗
Abstract 한글 요약
We review evidence for the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC). Initial approval of these agents in mCRPC was for patients with alterations in BRCA and other homologous recombination repair (HRR) genes. The European Medicines Agency has broadened approval of PARPi combinations with androgen receptor pathway inhibitors to all patients with mCRPC. Nevertheless, the greatest benefits are consistently observed for patients with mutations in BRCA and certain other HRR genes. The safety profile is consistent across all patient groups. PATIENT SUMMARY: Our mini review looks at the evidence for drugs called PARP inhibitors for metastatic prostate cancer that does not respond to standard hormone therapy (mCRPC for short). Combination treatment with a PARP inhibitor and another type of drug called an androgen receptor pathway inhibitor is approved in Europe for all patients with mCRPC, but those who are most likely to benefit have mutations in genes that are involved in a type of DNA repair.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.